Vertex Pharmaceuticals and Affinia Therapeutics have formed a pact to research engineered adeno-associated virus capsids for delivering gene therapies. Affinia will get $80 million in up-front and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback